Cytochrome P450 family 4 subfamily F member 11 (CYP4F11)

Cytochrome P450 family 4 subfamily F member 11 (CYP4F11) is a membrane-bound enzyme belonging to the cytochrome P450 superfamily of monooxygenases. It is involved in the omega-hydroxylation of various endogenous compounds including long-chain and 3-hydroxy fatty acids, eicosanoids (e.g., leukotriene B4, HETEs, lipoxins), cholesterol, vitamin K derivatives, and a range of exogenous drugs. CYP4F11 metabolizes both endogenous lipophilic substrates and xenobiotics, thus playing key roles in lipid homeostasis, modulation of inflammatory responses, and the detoxification or activation of drugs. Compared to other CYP4F family members, CYP4F11 has a broader substrate preference but generally lower catalytic efficiency towards eicosanoids. It is expressed in several tissues, including liver, kidney, brain, heart, and muscle, with overexpression noted in several cancers. The enzyme is considered a potential therapeutic target in oncology and metabolic disease contexts due to its role in 20-HETE production and fatty acid metabolism, though clinical targeting is complicated by broad substrate specificity and tissue distribution[1][4][6][7][9][11].

Other names

Cytochrome P450 4F11CYP4F11CYPIVF113-hydroxy fatty acids omega-hydroxylase CYP4F11Docosahexaenoic acid omega-hydroxylaseLong-chain fatty acid omega-monooxygenasePhylloquinone omega-hydroxylase CYP4F11

Omega-hydroxylation of fatty acids and eicosanoids, leading to their inactivation or clearance; Demethylation of xenobiotic drugs; Inhibition by small molecules (like HET0016) blocks 20-HETE production, affecting cell proliferation and migration in cancers.